Theoretical risk of genetic reassortment should not impede development of live, attenuated Rift Valley fever (RVF) vaccines commentary on the draft WHO RVF Target Product Profile

by Monath, Thomas P., Kortekaas, Jeroen, Watts, Douglas M., Christofferson, Rebecca C., Desiree LaBeaud, Angelle, Gowen, Brian, Peters, Clarence J., Smith, Darci R., Swanepoel, Robert, Morrill, John C., Ksiazek, Thomas G., Pittman, Phillip R., Bird, Brian H., Bettinger, George